药明康德强化长期确定性:CRDMO模式驱动 全年业绩有望创历史新高

每日经济新闻
Aug 03

近日,药明康德发布2025年中期报告。20.6%的营收同比增幅和101.9%的归母净利润同比增幅被外界视作药明康德“史上最强”中期业绩。同时,药明康德宣布调2025年全年收入目标至425亿至435亿元,其中持续经营业务预计将实现13%至17%双位数增长。  受到利好消息影响,药明康德不仅创下年内股价新高,也带动板块走势一路向上。  但值得强调的是,剥离投资收益因素,药明康德的上半年业绩更多是回归...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10